近年来，在创新药行业经历资本周期波动、一级市场投资趋于理性、二级市场对盈利能力产生更严苛要求的背景下，Biotech公司的资本路径选择已经不仅是简单的融资方式，还成为商业模式、技术路线、生态融入能力和长期价值的集体检验。市场越来越强调技术驱动、业绩可验证、商业可持续兼具的公司。在这一背景下，今日，百奥赛图敲钟科创板更具代表性意义。其“先H后A”两地上市的背后，是一家已实现盈利、现金流健康、硬核技术...
Source Link近年来，在创新药行业经历资本周期波动、一级市场投资趋于理性、二级市场对盈利能力产生更严苛要求的背景下，Biotech公司的资本路径选择已经不仅是简单的融资方式，还成为商业模式、技术路线、生态融入能力和长期价值的集体检验。市场越来越强调技术驱动、业绩可验证、商业可持续兼具的公司。在这一背景下，今日，百奥赛图敲钟科创板更具代表性意义。其“先H后A”两地上市的背后，是一家已实现盈利、现金流健康、硬核技术...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.